Genetic Technologies Limited
GENE · NASDAQ
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 21.2% | -12.7% | 9.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | 58.3% | -50% | -27% | -37.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | -$0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -72.3% | -130.4% | -101.1% | -129.8% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | -$0 | -$0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -116.6% | -162.2% | -138.8% | -131.4% |
| EPS | -1.13 | -1.59 | -1.95 | -1.69 |
| % Growth | 28.9% | 18.5% | -15.4% | – |
| EPS Diluted | -1.13 | -1.59 | -1.95 | -1.69 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -110.5% | -123.3% | -131.1% | -121.8% |